Table 2.
Circulating white blood cell counts in L-carnitine and placebo groups: 0, 12, and 24 weeks of supplementation.
| L-carnitine | Placebo | |||||
|---|---|---|---|---|---|---|
| 0 week | 12 weeks | 24 weeks | 0 week | 12 weeks | 24 weeks | |
| Leuko (109·L−1)∗ | 6.5 ± 0.5 | 6.0 ± 0.5 | 5.6 ± 0.4 | 6.3 ± 0.6 | 6.0 ± 0.7 | 5.8 ± 0.5 |
| Neutro (109·L−1) | 3.1 ± 0.3 | 3.0 ± 0.4 | 2.9 ± 0.3 | 3.2 ± 0.3 | 3.2 ± 0.4 | 3.3 ± 0.3 |
| Lympho (109·L−1)∗ | 2.5 ± 0.3 | 2.1 ± 0.2 | 2.0 ± 0.2 | 2.4 ± 0.4 | 2.1 ± 0.3 | 1.9 ± 0.2 |
| NLR | 1.4 ± 0.2 | 1.5 ± 0.2 | 1.6 ± 0.2 | 1.5 ± 0.2 | 1.6 ± 0.2 | 1.8 ± 0.2 |
| Mono (109·L−1)∗ | 0.56 ± 0.03 | 0.55 ± 0.04 | 0.50 ± 0.03 | 0.53 ± 0.06 | 0.47 ± 0.05 | 0.48 ± 0.06 |
| Platelets (109·L−1) | 285 ± 14 | 291 ± 14 | 282 ± 15 | 266 ± 18 | 268 ± 18 | 253 ± 18 |
∗ p < 0.05 main time effect. Leuko: leukocytes; Neutro: neutrophils; Lympho: lymphocytes; NLR: neutrophil-to-lymphocyte ratio (NLR); Mono: monocytes.